Prospects of immune checkpoint inhibitor therapy for advanced lung cancer

The discovery and application of tumor immune checkpoint therapy (ICIs) is a landmark event in the field of tumor treatment

As we all know, the main subtypes of lung cancer include small cell lung cancer (SCLC) in addition to NSCLC

The researchers included 38 randomized controlled trials and 41 studies that were eligible from January 2010 to May 2021

result:

For patients with NSCLC and SCLC, ICI is still an ideal treatment plan.

It is recommended that ICI+SOC is the best first-line treatment for SCLC patients

It is recommended that anti-PD-1/PD-L1+SOC and CTLA-4 antibodies be used for NSCLC patients who do not have mutated genes in the first-line and subsequent treatments

Immunotherapy is not recommended as a standard strategy for the follow-up treatment of SCLC

 

For patients with NSCLC and SCLC, ICI is still an ideal treatment plan.

It is recommended that ICI+SOC is the best first-line treatment for SCLC patients

It is recommended that anti-PD-1/PD-L1+SOC and CTLA-4 antibodies be used for NSCLC patients who do not have mutated genes in the first-line and subsequent treatments

Immunotherapy is not recommended as a standard strategy for the follow-up treatment of SCLC

source:

Chengdi Wang,et al.